WHO position paper on pneumococcal conjugate vaccines for children under 5 years of age
Client
Support WHO to draft and publish the position paper on pneumococcal conjugate vaccines in infants and children under 5 years of age.
Goal
- To support the WHO with the drafting and publication of the position paper on the use of pneumococcal conjugate vaccines (PCV) in children under 5 years of age.
Scope
WHO leveraged MMGH’s expertise in pneumococcal disease and drafting WHO position papers to support the drafting, finalizing and publishing of the position paper on PCV in infants and children under 5 years of age. The position paper summarises the evidence on the use of the currently available 10- and 13-valent PCV in children and presents WHO recommendations for their use.
Result
This position paper continues to provide guidance to WHO Member States on the use of PCV for preventing pneumococcal disease in children. MMGH subsequently supported WHO in writing an addendum to this paper on the use of PCV for outbreak response and on considerations for adult pneumococcal vaccination.
Focus Area
Policy & Strategy
Project Outputs
Pneumococcal conjugate vaccines in infants and children under 5 years of age